Recombinant factor VIIa (NovoSeven®) as a hemostatic agent after surgery for congenital heart disease
Background : Postoperative bleeding and blood product requirements can be substantial in children undergoing open-heart surgery, and reexploration is required in 1% of cases. Recombinant activated factor VII (rFVIIa, NovoSeven®, NovoNordisk, Denmark) is a hemostatic agent approved for the treatment...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
RAZON, YARON - MD [verfasserIn] EREZ, ELDAD - MD [verfasserIn] VIDNE, BERNARDO - MD [verfasserIn] BIRK, EINAT - MD KATZ, JACOB - MD TAMARI, HANNA - MD DAGAN, OVADIA - MD |
|---|
| Format: |
E-Artikel |
|---|
| Erschienen: |
Oxford, UK: Blackwell Publishing Ltd ; 2005 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
Online-Ressource |
|---|
| Reproduktion: |
2005 ; Blackwell Publishing Journal Backfiles 1879-2005 |
|---|---|
| Übergeordnetes Werk: |
In: Pediatric anesthesia - Oxford [u.a.] : Wiley-Blackwell, 1991, 15(2005), 3, Seite 0 |
| Übergeordnetes Werk: |
volume:15 ; year:2005 ; number:3 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1111/j.1460-9592.2005.01429.x |
|---|
| Katalog-ID: |
NLEJ243864833 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ243864833 | ||
| 003 | DE-627 | ||
| 005 | 20230505211519.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 120427s2005 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/j.1460-9592.2005.01429.x |2 doi | |
| 035 | |a (DE-627)NLEJ243864833 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 100 | 1 | |a RAZON, YARON |c MD |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recombinant factor VIIa (NovoSeven®) as a hemostatic agent after surgery for congenital heart disease |
| 264 | 1 | |a Oxford, UK |b Blackwell Publishing Ltd |c 2005 | |
| 300 | |a Online-Ressource | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Background : Postoperative bleeding and blood product requirements can be substantial in children undergoing open-heart surgery, and reexploration is required in 1% of cases. Recombinant activated factor VII (rFVIIa, NovoSeven®, NovoNordisk, Denmark) is a hemostatic agent approved for the treatment of hemophilic patients with inhibitors to factor VIII or factor IX. It has also been used with success in other conditions. We present our experience with rFVIIa treatment for uncontrolled bleeding after open-heart surgery in five pediatric patients.Methods : The study group consisted of five patients after open-heart surgery with excessive blood loss. The patients were treated with rFVIIa after failure of conventional treatment to control the bleeding. Blood loss, blood product consumption, and coagulation test results were recorded before and after rFVIIa administration.Results : In all cases, blood loss decreased considerably after rFVIIa administration (mean 7.8 ml·kg−1·h−1), almost eliminating the need for additional blood products, and the prolonged prothrombin time normalized. In two patients with thrombocytopathy, rFVIIa helped to discriminate surgical bleeding from bleeding caused by a defect in hemostasis. No side effects of rFVIIa treatment were noted.Conclusions : These cases support the impression that RFVIIa is efficient and safe in correcting hemostasis in children after cardiopulmonary bypass when other means fail. However, the data are still limited, and more extensive research is needed. | ||
| 533 | |d 2005 |f Blackwell Publishing Journal Backfiles 1879-2005 |7 |2005|||||||||| | ||
| 650 | 4 | |a cardiopulmonary bypass | |
| 700 | 1 | |a EREZ, ELDAD |c MD |e verfasserin |4 aut | |
| 700 | 1 | |a VIDNE, BERNARDO |c MD |e verfasserin |4 aut | |
| 700 | 1 | |a BIRK, EINAT |c MD |4 oth | |
| 700 | 1 | |a KATZ, JACOB |c MD |4 oth | |
| 700 | 1 | |a TAMARI, HANNA |c MD |4 oth | |
| 700 | 1 | |a DAGAN, OVADIA |c MD |4 oth | |
| 773 | 0 | 8 | |i In |t Pediatric anesthesia |d Oxford [u.a.] : Wiley-Blackwell, 1991 |g 15(2005), 3, Seite 0 |h Online-Ressource |w (DE-627)NLEJ243926200 |w (DE-600)2008564-3 |x 1460-9592 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2005 |g number:3 |g pages:0 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/j.1460-9592.2005.01429.x |q text/html |x Verlag |z Deutschlandweit zugänglich |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-DJB | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2005 |e 3 |h 0 | ||
| author_variant |
y r yr e e ee b v bv |
|---|---|
| matchkey_str |
article:14609592:2005----::eobnnfcovinvsvnshmsaiaetfesreyo |
| hierarchy_sort_str |
2005 |
| publishDate |
2005 |
| allfields |
10.1111/j.1460-9592.2005.01429.x doi (DE-627)NLEJ243864833 DE-627 ger DE-627 rakwb RAZON, YARON MD verfasserin aut Recombinant factor VIIa (NovoSeven®) as a hemostatic agent after surgery for congenital heart disease Oxford, UK Blackwell Publishing Ltd 2005 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Background : Postoperative bleeding and blood product requirements can be substantial in children undergoing open-heart surgery, and reexploration is required in 1% of cases. Recombinant activated factor VII (rFVIIa, NovoSeven®, NovoNordisk, Denmark) is a hemostatic agent approved for the treatment of hemophilic patients with inhibitors to factor VIII or factor IX. It has also been used with success in other conditions. We present our experience with rFVIIa treatment for uncontrolled bleeding after open-heart surgery in five pediatric patients.Methods : The study group consisted of five patients after open-heart surgery with excessive blood loss. The patients were treated with rFVIIa after failure of conventional treatment to control the bleeding. Blood loss, blood product consumption, and coagulation test results were recorded before and after rFVIIa administration.Results : In all cases, blood loss decreased considerably after rFVIIa administration (mean 7.8 ml·kg−1·h−1), almost eliminating the need for additional blood products, and the prolonged prothrombin time normalized. In two patients with thrombocytopathy, rFVIIa helped to discriminate surgical bleeding from bleeding caused by a defect in hemostasis. No side effects of rFVIIa treatment were noted.Conclusions : These cases support the impression that RFVIIa is efficient and safe in correcting hemostasis in children after cardiopulmonary bypass when other means fail. However, the data are still limited, and more extensive research is needed. 2005 Blackwell Publishing Journal Backfiles 1879-2005 |2005|||||||||| cardiopulmonary bypass EREZ, ELDAD MD verfasserin aut VIDNE, BERNARDO MD verfasserin aut BIRK, EINAT MD oth KATZ, JACOB MD oth TAMARI, HANNA MD oth DAGAN, OVADIA MD oth In Pediatric anesthesia Oxford [u.a.] : Wiley-Blackwell, 1991 15(2005), 3, Seite 0 Online-Ressource (DE-627)NLEJ243926200 (DE-600)2008564-3 1460-9592 nnns volume:15 year:2005 number:3 pages:0 http://dx.doi.org/10.1111/j.1460-9592.2005.01429.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 15 2005 3 0 |
| spelling |
10.1111/j.1460-9592.2005.01429.x doi (DE-627)NLEJ243864833 DE-627 ger DE-627 rakwb RAZON, YARON MD verfasserin aut Recombinant factor VIIa (NovoSeven®) as a hemostatic agent after surgery for congenital heart disease Oxford, UK Blackwell Publishing Ltd 2005 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Background : Postoperative bleeding and blood product requirements can be substantial in children undergoing open-heart surgery, and reexploration is required in 1% of cases. Recombinant activated factor VII (rFVIIa, NovoSeven®, NovoNordisk, Denmark) is a hemostatic agent approved for the treatment of hemophilic patients with inhibitors to factor VIII or factor IX. It has also been used with success in other conditions. We present our experience with rFVIIa treatment for uncontrolled bleeding after open-heart surgery in five pediatric patients.Methods : The study group consisted of five patients after open-heart surgery with excessive blood loss. The patients were treated with rFVIIa after failure of conventional treatment to control the bleeding. Blood loss, blood product consumption, and coagulation test results were recorded before and after rFVIIa administration.Results : In all cases, blood loss decreased considerably after rFVIIa administration (mean 7.8 ml·kg−1·h−1), almost eliminating the need for additional blood products, and the prolonged prothrombin time normalized. In two patients with thrombocytopathy, rFVIIa helped to discriminate surgical bleeding from bleeding caused by a defect in hemostasis. No side effects of rFVIIa treatment were noted.Conclusions : These cases support the impression that RFVIIa is efficient and safe in correcting hemostasis in children after cardiopulmonary bypass when other means fail. However, the data are still limited, and more extensive research is needed. 2005 Blackwell Publishing Journal Backfiles 1879-2005 |2005|||||||||| cardiopulmonary bypass EREZ, ELDAD MD verfasserin aut VIDNE, BERNARDO MD verfasserin aut BIRK, EINAT MD oth KATZ, JACOB MD oth TAMARI, HANNA MD oth DAGAN, OVADIA MD oth In Pediatric anesthesia Oxford [u.a.] : Wiley-Blackwell, 1991 15(2005), 3, Seite 0 Online-Ressource (DE-627)NLEJ243926200 (DE-600)2008564-3 1460-9592 nnns volume:15 year:2005 number:3 pages:0 http://dx.doi.org/10.1111/j.1460-9592.2005.01429.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 15 2005 3 0 |
| allfields_unstemmed |
10.1111/j.1460-9592.2005.01429.x doi (DE-627)NLEJ243864833 DE-627 ger DE-627 rakwb RAZON, YARON MD verfasserin aut Recombinant factor VIIa (NovoSeven®) as a hemostatic agent after surgery for congenital heart disease Oxford, UK Blackwell Publishing Ltd 2005 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Background : Postoperative bleeding and blood product requirements can be substantial in children undergoing open-heart surgery, and reexploration is required in 1% of cases. Recombinant activated factor VII (rFVIIa, NovoSeven®, NovoNordisk, Denmark) is a hemostatic agent approved for the treatment of hemophilic patients with inhibitors to factor VIII or factor IX. It has also been used with success in other conditions. We present our experience with rFVIIa treatment for uncontrolled bleeding after open-heart surgery in five pediatric patients.Methods : The study group consisted of five patients after open-heart surgery with excessive blood loss. The patients were treated with rFVIIa after failure of conventional treatment to control the bleeding. Blood loss, blood product consumption, and coagulation test results were recorded before and after rFVIIa administration.Results : In all cases, blood loss decreased considerably after rFVIIa administration (mean 7.8 ml·kg−1·h−1), almost eliminating the need for additional blood products, and the prolonged prothrombin time normalized. In two patients with thrombocytopathy, rFVIIa helped to discriminate surgical bleeding from bleeding caused by a defect in hemostasis. No side effects of rFVIIa treatment were noted.Conclusions : These cases support the impression that RFVIIa is efficient and safe in correcting hemostasis in children after cardiopulmonary bypass when other means fail. However, the data are still limited, and more extensive research is needed. 2005 Blackwell Publishing Journal Backfiles 1879-2005 |2005|||||||||| cardiopulmonary bypass EREZ, ELDAD MD verfasserin aut VIDNE, BERNARDO MD verfasserin aut BIRK, EINAT MD oth KATZ, JACOB MD oth TAMARI, HANNA MD oth DAGAN, OVADIA MD oth In Pediatric anesthesia Oxford [u.a.] : Wiley-Blackwell, 1991 15(2005), 3, Seite 0 Online-Ressource (DE-627)NLEJ243926200 (DE-600)2008564-3 1460-9592 nnns volume:15 year:2005 number:3 pages:0 http://dx.doi.org/10.1111/j.1460-9592.2005.01429.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 15 2005 3 0 |
| allfieldsGer |
10.1111/j.1460-9592.2005.01429.x doi (DE-627)NLEJ243864833 DE-627 ger DE-627 rakwb RAZON, YARON MD verfasserin aut Recombinant factor VIIa (NovoSeven®) as a hemostatic agent after surgery for congenital heart disease Oxford, UK Blackwell Publishing Ltd 2005 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Background : Postoperative bleeding and blood product requirements can be substantial in children undergoing open-heart surgery, and reexploration is required in 1% of cases. Recombinant activated factor VII (rFVIIa, NovoSeven®, NovoNordisk, Denmark) is a hemostatic agent approved for the treatment of hemophilic patients with inhibitors to factor VIII or factor IX. It has also been used with success in other conditions. We present our experience with rFVIIa treatment for uncontrolled bleeding after open-heart surgery in five pediatric patients.Methods : The study group consisted of five patients after open-heart surgery with excessive blood loss. The patients were treated with rFVIIa after failure of conventional treatment to control the bleeding. Blood loss, blood product consumption, and coagulation test results were recorded before and after rFVIIa administration.Results : In all cases, blood loss decreased considerably after rFVIIa administration (mean 7.8 ml·kg−1·h−1), almost eliminating the need for additional blood products, and the prolonged prothrombin time normalized. In two patients with thrombocytopathy, rFVIIa helped to discriminate surgical bleeding from bleeding caused by a defect in hemostasis. No side effects of rFVIIa treatment were noted.Conclusions : These cases support the impression that RFVIIa is efficient and safe in correcting hemostasis in children after cardiopulmonary bypass when other means fail. However, the data are still limited, and more extensive research is needed. 2005 Blackwell Publishing Journal Backfiles 1879-2005 |2005|||||||||| cardiopulmonary bypass EREZ, ELDAD MD verfasserin aut VIDNE, BERNARDO MD verfasserin aut BIRK, EINAT MD oth KATZ, JACOB MD oth TAMARI, HANNA MD oth DAGAN, OVADIA MD oth In Pediatric anesthesia Oxford [u.a.] : Wiley-Blackwell, 1991 15(2005), 3, Seite 0 Online-Ressource (DE-627)NLEJ243926200 (DE-600)2008564-3 1460-9592 nnns volume:15 year:2005 number:3 pages:0 http://dx.doi.org/10.1111/j.1460-9592.2005.01429.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 15 2005 3 0 |
| allfieldsSound |
10.1111/j.1460-9592.2005.01429.x doi (DE-627)NLEJ243864833 DE-627 ger DE-627 rakwb RAZON, YARON MD verfasserin aut Recombinant factor VIIa (NovoSeven®) as a hemostatic agent after surgery for congenital heart disease Oxford, UK Blackwell Publishing Ltd 2005 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Background : Postoperative bleeding and blood product requirements can be substantial in children undergoing open-heart surgery, and reexploration is required in 1% of cases. Recombinant activated factor VII (rFVIIa, NovoSeven®, NovoNordisk, Denmark) is a hemostatic agent approved for the treatment of hemophilic patients with inhibitors to factor VIII or factor IX. It has also been used with success in other conditions. We present our experience with rFVIIa treatment for uncontrolled bleeding after open-heart surgery in five pediatric patients.Methods : The study group consisted of five patients after open-heart surgery with excessive blood loss. The patients were treated with rFVIIa after failure of conventional treatment to control the bleeding. Blood loss, blood product consumption, and coagulation test results were recorded before and after rFVIIa administration.Results : In all cases, blood loss decreased considerably after rFVIIa administration (mean 7.8 ml·kg−1·h−1), almost eliminating the need for additional blood products, and the prolonged prothrombin time normalized. In two patients with thrombocytopathy, rFVIIa helped to discriminate surgical bleeding from bleeding caused by a defect in hemostasis. No side effects of rFVIIa treatment were noted.Conclusions : These cases support the impression that RFVIIa is efficient and safe in correcting hemostasis in children after cardiopulmonary bypass when other means fail. However, the data are still limited, and more extensive research is needed. 2005 Blackwell Publishing Journal Backfiles 1879-2005 |2005|||||||||| cardiopulmonary bypass EREZ, ELDAD MD verfasserin aut VIDNE, BERNARDO MD verfasserin aut BIRK, EINAT MD oth KATZ, JACOB MD oth TAMARI, HANNA MD oth DAGAN, OVADIA MD oth In Pediatric anesthesia Oxford [u.a.] : Wiley-Blackwell, 1991 15(2005), 3, Seite 0 Online-Ressource (DE-627)NLEJ243926200 (DE-600)2008564-3 1460-9592 nnns volume:15 year:2005 number:3 pages:0 http://dx.doi.org/10.1111/j.1460-9592.2005.01429.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 15 2005 3 0 |
| source |
In Pediatric anesthesia 15(2005), 3, Seite 0 volume:15 year:2005 number:3 pages:0 |
| sourceStr |
In Pediatric anesthesia 15(2005), 3, Seite 0 volume:15 year:2005 number:3 pages:0 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
cardiopulmonary bypass |
| isfreeaccess_bool |
false |
| container_title |
Pediatric anesthesia |
| authorswithroles_txt_mv |
RAZON, YARON @@aut@@ EREZ, ELDAD @@aut@@ VIDNE, BERNARDO @@aut@@ BIRK, EINAT @@oth@@ KATZ, JACOB @@oth@@ TAMARI, HANNA @@oth@@ DAGAN, OVADIA @@oth@@ |
| publishDateDaySort_date |
2005-01-01T00:00:00Z |
| hierarchy_top_id |
NLEJ243926200 |
| id |
NLEJ243864833 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ243864833</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505211519.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2005 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1111/j.1460-9592.2005.01429.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ243864833</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">RAZON, YARON</subfield><subfield code="c">MD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Recombinant factor VIIa (NovoSeven®) as a hemostatic agent after surgery for congenital heart disease</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Publishing Ltd</subfield><subfield code="c">2005</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background : Postoperative bleeding and blood product requirements can be substantial in children undergoing open-heart surgery, and reexploration is required in 1% of cases. Recombinant activated factor VII (rFVIIa, NovoSeven®, NovoNordisk, Denmark) is a hemostatic agent approved for the treatment of hemophilic patients with inhibitors to factor VIII or factor IX. It has also been used with success in other conditions. We present our experience with rFVIIa treatment for uncontrolled bleeding after open-heart surgery in five pediatric patients.Methods : The study group consisted of five patients after open-heart surgery with excessive blood loss. The patients were treated with rFVIIa after failure of conventional treatment to control the bleeding. Blood loss, blood product consumption, and coagulation test results were recorded before and after rFVIIa administration.Results : In all cases, blood loss decreased considerably after rFVIIa administration (mean 7.8 ml·kg−1·h−1), almost eliminating the need for additional blood products, and the prolonged prothrombin time normalized. In two patients with thrombocytopathy, rFVIIa helped to discriminate surgical bleeding from bleeding caused by a defect in hemostasis. No side effects of rFVIIa treatment were noted.Conclusions : These cases support the impression that RFVIIa is efficient and safe in correcting hemostasis in children after cardiopulmonary bypass when other means fail. However, the data are still limited, and more extensive research is needed.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2005</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2005||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cardiopulmonary bypass</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">EREZ, ELDAD</subfield><subfield code="c">MD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">VIDNE, BERNARDO</subfield><subfield code="c">MD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">BIRK, EINAT</subfield><subfield code="c">MD</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">KATZ, JACOB</subfield><subfield code="c">MD</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">TAMARI, HANNA</subfield><subfield code="c">MD</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">DAGAN, OVADIA</subfield><subfield code="c">MD</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Pediatric anesthesia</subfield><subfield code="d">Oxford [u.a.] : Wiley-Blackwell, 1991</subfield><subfield code="g">15(2005), 3, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243926200</subfield><subfield code="w">(DE-600)2008564-3</subfield><subfield code="x">1460-9592</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2005</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1111/j.1460-9592.2005.01429.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2005</subfield><subfield code="e">3</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| series2 |
Blackwell Publishing Journal Backfiles 1879-2005 |
| author |
RAZON, YARON MD |
| spellingShingle |
RAZON, YARON MD misc cardiopulmonary bypass Recombinant factor VIIa (NovoSeven®) as a hemostatic agent after surgery for congenital heart disease |
| authorStr |
RAZON, YARON MD |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ243926200 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
NL |
| publishPlace |
Oxford, UK |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1460-9592 |
| topic_title |
Recombinant factor VIIa (NovoSeven®) as a hemostatic agent after surgery for congenital heart disease cardiopulmonary bypass |
| publisher |
Blackwell Publishing Ltd |
| publisherStr |
Blackwell Publishing Ltd |
| topic |
misc cardiopulmonary bypass |
| topic_unstemmed |
misc cardiopulmonary bypass |
| topic_browse |
misc cardiopulmonary bypass |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
e b eb j k jk h t ht o d od |
| hierarchy_parent_title |
Pediatric anesthesia |
| hierarchy_parent_id |
NLEJ243926200 |
| hierarchy_top_title |
Pediatric anesthesia |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ243926200 (DE-600)2008564-3 |
| title |
Recombinant factor VIIa (NovoSeven®) as a hemostatic agent after surgery for congenital heart disease |
| ctrlnum |
(DE-627)NLEJ243864833 |
| title_full |
Recombinant factor VIIa (NovoSeven®) as a hemostatic agent after surgery for congenital heart disease |
| author_sort |
RAZON, YARON MD |
| journal |
Pediatric anesthesia |
| journalStr |
Pediatric anesthesia |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2005 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
RAZON, YARON EREZ, ELDAD VIDNE, BERNARDO |
| container_volume |
15 |
| physical |
Online-Ressource |
| format_se |
Elektronische Aufsätze |
| author-letter |
RAZON, YARON |
| doi_str_mv |
10.1111/j.1460-9592.2005.01429.x |
| author2-role |
verfasserin |
| title_sort |
recombinant factor viia (novoseven®) as a hemostatic agent after surgery for congenital heart disease |
| title_auth |
Recombinant factor VIIa (NovoSeven®) as a hemostatic agent after surgery for congenital heart disease |
| abstract |
Background : Postoperative bleeding and blood product requirements can be substantial in children undergoing open-heart surgery, and reexploration is required in 1% of cases. Recombinant activated factor VII (rFVIIa, NovoSeven®, NovoNordisk, Denmark) is a hemostatic agent approved for the treatment of hemophilic patients with inhibitors to factor VIII or factor IX. It has also been used with success in other conditions. We present our experience with rFVIIa treatment for uncontrolled bleeding after open-heart surgery in five pediatric patients.Methods : The study group consisted of five patients after open-heart surgery with excessive blood loss. The patients were treated with rFVIIa after failure of conventional treatment to control the bleeding. Blood loss, blood product consumption, and coagulation test results were recorded before and after rFVIIa administration.Results : In all cases, blood loss decreased considerably after rFVIIa administration (mean 7.8 ml·kg−1·h−1), almost eliminating the need for additional blood products, and the prolonged prothrombin time normalized. In two patients with thrombocytopathy, rFVIIa helped to discriminate surgical bleeding from bleeding caused by a defect in hemostasis. No side effects of rFVIIa treatment were noted.Conclusions : These cases support the impression that RFVIIa is efficient and safe in correcting hemostasis in children after cardiopulmonary bypass when other means fail. However, the data are still limited, and more extensive research is needed. |
| abstractGer |
Background : Postoperative bleeding and blood product requirements can be substantial in children undergoing open-heart surgery, and reexploration is required in 1% of cases. Recombinant activated factor VII (rFVIIa, NovoSeven®, NovoNordisk, Denmark) is a hemostatic agent approved for the treatment of hemophilic patients with inhibitors to factor VIII or factor IX. It has also been used with success in other conditions. We present our experience with rFVIIa treatment for uncontrolled bleeding after open-heart surgery in five pediatric patients.Methods : The study group consisted of five patients after open-heart surgery with excessive blood loss. The patients were treated with rFVIIa after failure of conventional treatment to control the bleeding. Blood loss, blood product consumption, and coagulation test results were recorded before and after rFVIIa administration.Results : In all cases, blood loss decreased considerably after rFVIIa administration (mean 7.8 ml·kg−1·h−1), almost eliminating the need for additional blood products, and the prolonged prothrombin time normalized. In two patients with thrombocytopathy, rFVIIa helped to discriminate surgical bleeding from bleeding caused by a defect in hemostasis. No side effects of rFVIIa treatment were noted.Conclusions : These cases support the impression that RFVIIa is efficient and safe in correcting hemostasis in children after cardiopulmonary bypass when other means fail. However, the data are still limited, and more extensive research is needed. |
| abstract_unstemmed |
Background : Postoperative bleeding and blood product requirements can be substantial in children undergoing open-heart surgery, and reexploration is required in 1% of cases. Recombinant activated factor VII (rFVIIa, NovoSeven®, NovoNordisk, Denmark) is a hemostatic agent approved for the treatment of hemophilic patients with inhibitors to factor VIII or factor IX. It has also been used with success in other conditions. We present our experience with rFVIIa treatment for uncontrolled bleeding after open-heart surgery in five pediatric patients.Methods : The study group consisted of five patients after open-heart surgery with excessive blood loss. The patients were treated with rFVIIa after failure of conventional treatment to control the bleeding. Blood loss, blood product consumption, and coagulation test results were recorded before and after rFVIIa administration.Results : In all cases, blood loss decreased considerably after rFVIIa administration (mean 7.8 ml·kg−1·h−1), almost eliminating the need for additional blood products, and the prolonged prothrombin time normalized. In two patients with thrombocytopathy, rFVIIa helped to discriminate surgical bleeding from bleeding caused by a defect in hemostasis. No side effects of rFVIIa treatment were noted.Conclusions : These cases support the impression that RFVIIa is efficient and safe in correcting hemostasis in children after cardiopulmonary bypass when other means fail. However, the data are still limited, and more extensive research is needed. |
| collection_details |
GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE |
| container_issue |
3 |
| title_short |
Recombinant factor VIIa (NovoSeven®) as a hemostatic agent after surgery for congenital heart disease |
| url |
http://dx.doi.org/10.1111/j.1460-9592.2005.01429.x |
| remote_bool |
true |
| author2 |
EREZ, ELDAD MD VIDNE, BERNARDO MD BIRK, EINAT MD KATZ, JACOB MD TAMARI, HANNA MD DAGAN, OVADIA MD |
| author2Str |
EREZ, ELDAD MD VIDNE, BERNARDO MD BIRK, EINAT MD KATZ, JACOB MD TAMARI, HANNA MD DAGAN, OVADIA MD |
| ppnlink |
NLEJ243926200 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth |
| doi_str |
10.1111/j.1460-9592.2005.01429.x |
| up_date |
2024-07-06T06:46:33.093Z |
| _version_ |
1803811179037982720 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ243864833</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505211519.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2005 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1111/j.1460-9592.2005.01429.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ243864833</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">RAZON, YARON</subfield><subfield code="c">MD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Recombinant factor VIIa (NovoSeven®) as a hemostatic agent after surgery for congenital heart disease</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Publishing Ltd</subfield><subfield code="c">2005</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background : Postoperative bleeding and blood product requirements can be substantial in children undergoing open-heart surgery, and reexploration is required in 1% of cases. Recombinant activated factor VII (rFVIIa, NovoSeven®, NovoNordisk, Denmark) is a hemostatic agent approved for the treatment of hemophilic patients with inhibitors to factor VIII or factor IX. It has also been used with success in other conditions. We present our experience with rFVIIa treatment for uncontrolled bleeding after open-heart surgery in five pediatric patients.Methods : The study group consisted of five patients after open-heart surgery with excessive blood loss. The patients were treated with rFVIIa after failure of conventional treatment to control the bleeding. Blood loss, blood product consumption, and coagulation test results were recorded before and after rFVIIa administration.Results : In all cases, blood loss decreased considerably after rFVIIa administration (mean 7.8 ml·kg−1·h−1), almost eliminating the need for additional blood products, and the prolonged prothrombin time normalized. In two patients with thrombocytopathy, rFVIIa helped to discriminate surgical bleeding from bleeding caused by a defect in hemostasis. No side effects of rFVIIa treatment were noted.Conclusions : These cases support the impression that RFVIIa is efficient and safe in correcting hemostasis in children after cardiopulmonary bypass when other means fail. However, the data are still limited, and more extensive research is needed.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2005</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2005||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">cardiopulmonary bypass</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">EREZ, ELDAD</subfield><subfield code="c">MD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">VIDNE, BERNARDO</subfield><subfield code="c">MD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">BIRK, EINAT</subfield><subfield code="c">MD</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">KATZ, JACOB</subfield><subfield code="c">MD</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">TAMARI, HANNA</subfield><subfield code="c">MD</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">DAGAN, OVADIA</subfield><subfield code="c">MD</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Pediatric anesthesia</subfield><subfield code="d">Oxford [u.a.] : Wiley-Blackwell, 1991</subfield><subfield code="g">15(2005), 3, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243926200</subfield><subfield code="w">(DE-600)2008564-3</subfield><subfield code="x">1460-9592</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2005</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1111/j.1460-9592.2005.01429.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2005</subfield><subfield code="e">3</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.401638 |